CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- 4 Planned sale CMO & EVP Dev & Med Affairs sold 3,109 shares at an average $253.43 ($787,904)
- 4 Planned sale CMO & EVP Dev & Med Affairs sold 52,592 shares at $285.00 ($14,988,720)
- 4 Planned sale Director sold 11,250 shares at $275.00 ($3,093,750)
- 4 Planned sale CMO & EVP Dev & Med Affairs sold 1,752 shares at an average $251.00 ($439,760)
- 4 Open-market sale Chief Executive Officer sold 5,219 shares at an average $250.98 ($1,309,853)
- 4 Open-market sale CMO & EVP Dev & Med Affairs sold 1,682 shares at an average $250.98 ($422,144)
- 4 Open-market sale EVP, Chief Financial Officer sold 1,682 shares at an average $250.98 ($422,144)
- 4 Open-market sale EVP, Chief Commercial Officer sold 1,469 shares at an average $250.98 ($368,686)
- 4 Planned sale CSO & EVP, Head of Research sold 3,000 shares at an average $251.65 ($754,947)
- 4 Grant or award CMO & EVP Dev & Med Affairs acquired 96 shares (grant or award)
- 4 Grant or award EVP, CLO and Secretary acquired 7,245 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 15,000 shares at $280.00 ($4,200,000)
- 4 Planned sale CSO & EVP, Head of Research sold 22,025 shares at an average $270.99 ($5,968,516)
- 4 Planned sale Director sold 20,250 shares at an average $262.00 ($5,305,586)
- 4 Planned sale Chief Executive Officer sold 15,148 shares at $270.00 ($4,089,960)
- 4 Planned sale Chief Executive Officer sold 7,093 shares at $261.00 ($1,851,273)
- 4 Planned sale Director sold 8,500 shares at $240.00 ($2,040,000)
- 4 Planned sale Director sold 32,450 shares at an average $220.69 ($7,161,360)
- 4 Open-market sale CMO & EVP Dev & Med Affairs sold 2,103 shares at an average $230.99 ($485,773)
Page 6 of 47 · 936 filings